Disclosure: I personal stock in AstraZeneca, a single of the companies pointed out in this commentary.
A group of 6 Taiwanese scientists has announced what might be a lengthy hoped-for breakthrough in the battle against Alzheimer’s disease. They have found that statins, a family members of drugs originally produced to decrease cholesterol amounts, seem to reduce the risk of dementia by as much as a single-quarter.
The team, led by Jui-Ming Chen of Asia University in Taichung and Cheng-Wei Chang of Hsing Wu University in Taipei, has published its findings in PLOSONE, a peer-reviewed open-access journal of the Public Library of Science (PLOS). Their paper can be accessed here.
It is nevertheless early days however, of course, and the fact that statins are connected with a lowered threat of Alzheimer’s might not suggest they are the causal agent.
Nonetheless the findings contribute to a increasing realization that the discovery of statins constitutes one particular of the most crucial developments in present day pharmacological history. The discovery was created in the early 1970s by Akira Endo, a biochemist functioning for Tokyo-based mostly Sankyo Company. Endo was awarded the prestigious Lasker Prize in 2008.
Aside from Sankyo, other Japanese firms that have played a crucial function in establishing statins incorporate Nissan Chemical Industries, Kowa Pharmaceuticals, and Shionogi.
In the United States, the most widespread kinds of statins are manufactured by, amongst other corporations, Pfizer (below the brandname Lipitor), Merck (Zocor), and Bristol-Myers Squibb (Pravachol). Other versions are offered for Swiss-based mostly Novartis and British-based AstraZeneca.
Teva of Israel and Ranbaxy of India make generic versions
From Taiwan, A Extended Hoped-For Breakthrough In The Battle Against Alzheimer"s
Hiç yorum yok:
Yorum Gönder